Compounds > sb 203580
Page last updated: 2024-09-05

sb 203580 and regorafenib

sb 203580 has been researched along with regorafenib in 3 studies

Compound Research Comparison

Studies
(sb 203580)		Trials
(sb 203580)		Recent Studies (post-2010)
(sb 203580)		Studies
(regorafenib)		Trials
(regorafenib)		Recent Studies (post-2010) (regorafenib)
3,48941,137884122857

Protein Interaction Comparison

ProteinTaxonomysb 203580 (IC50)regorafenib (IC50)
RAF proto-oncogene serine/threonine-protein kinaseHomo sapiens (human)0.002
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.0015
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0015
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.5043
Fibroblast growth factor receptor 1Homo sapiens (human)0.1018
Serine/threonine-protein kinase B-rafHomo sapiens (human)0.0226
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.0092
Bifunctional epoxide hydrolase 2Homo sapiens (human)0.0005
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.046
Vascular endothelial growth factor receptor 3Mus musculus (house mouse)0.0015
Vascular endothelial growth factor receptor 2Mus musculus (house mouse)0.0015
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.0043
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.082
Angiopoietin-1 receptorHomo sapiens (human)0.1562
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)3

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Bharate, SB; Raghuvanshi, R1
Chiang, CH; Chung, JG; Hsu, FT1

Other Studies

3 other study(ies) available for sb 203580 and regorafenib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Recent Developments in the Use of Kinase Inhibitors for Management of Viral Infections.
    Journal of medicinal chemistry, 2022, 01-27, Volume: 65, Issue:2

    Topics: Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Drug Approval; Drug Repositioning; High-Throughput Screening Assays; Humans; Protein Kinase Inhibitors; SARS-CoV-2; United States; United States Food and Drug Administration; Virus Diseases

2022
Regorefenib induces extrinsic/intrinsic apoptosis and inhibits MAPK/NF-κB-modulated tumor progression in bladder cancer in vitro and in vivo.
    Environmental toxicology, 2019, Volume: 34, Issue:6

    Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Survival; Disease Progression; Humans; Imidazoles; MAP Kinase Signaling System; Mice; Mitogen-Activated Protein Kinases; Neoplasm Transplantation; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Phenylurea Compounds; Pyridines; Signal Transduction; Urinary Bladder Neoplasms

2019